Ascentage Pharma Group International (AAPG)vsVertex Pharmaceuticals Inc (VRTX)
AAPG
Ascentage Pharma Group International
$15.43
+1.98%
HEALTHCARE · Cap: $1.40B
VRTX
Vertex Pharmaceuticals Inc
$547.09
+0.85%
HEALTHCARE · Cap: $141.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1859% more annual revenue ($12.59B vs $642.63M). VRTX leads profitability with a 35.0% profit margin vs -228.5%. VRTX earns a higher WallStSmart Score of 62/100 (C+).
AAPG
Avoid25
out of 100
Grade: F
VRTX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
+42.4%
Fair Value
$949.93
Current Price
$547.09
$402.84 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 29.3% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Trading at 17.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.76 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AAPG profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.66 — expect wider price swings.
AAPG is growing revenue faster at 29.3% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (62/100 vs 25/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?